Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 122

1.

Erratum.

Bushinsky DA, Chertow GM, Cheng S, Deng H, Kopyt N, Martin KJ, Rastogi A, Ureña-Torres P, Vervloet M, Block GA.

Nephrol Dial Transplant. 2019 May 15. pii: gfz111. doi: 10.1093/ndt/gfz111. [Epub ahead of print] No abstract available.

PMID:
31093680
2.

Effects of Nicotinamide and Lanthanum Carbonate on Serum Phosphate and Fibroblast Growth Factor-23 in CKD: The COMBINE Trial.

Ix JH, Isakova T, Larive B, Raphael KL, Raj DS, Cheung AK, Sprague SM, Fried LF, Gassman JJ, Middleton JP, Flessner MF, Block GA, Wolf M.

J Am Soc Nephrol. 2019 Jun;30(6):1096-1108. doi: 10.1681/ASN.2018101058. Epub 2019 May 13.

PMID:
31085679
3.

Serum Calcification Propensity and Coronary Artery Calcification Among Patients With CKD: The CRIC (Chronic Renal Insufficiency Cohort) Study.

Bundy JD, Cai X, Scialla JJ, Dobre MA, Chen J, Hsu CY, Leonard MB, Go AS, Rao PS, Lash JP, Townsend RR, Feldman HI, de Boer IH, Block GA, Wolf M, Smith ER, Pasch A, Isakova T; CRIC Study Investigators.

Am J Kidney Dis. 2019 Jun;73(6):806-814. doi: 10.1053/j.ajkd.2019.01.024. Epub 2019 Mar 29.

PMID:
30935773
4.

An integrated analysis of safety and tolerability of etelcalcetide in patients receiving hemodialysis with secondary hyperparathyroidism.

Block GA, Chertow GM, Sullivan JT, Deng H, Mather O, Tomlin H, Serenko M.

PLoS One. 2019 Mar 15;14(3):e0213774. doi: 10.1371/journal.pone.0213774. eCollection 2019.

5.

One-year safety and efficacy of intravenous etelcalcetide in patients on hemodialysis with secondary hyperparathyroidism.

Bushinsky DA, Chertow GM, Cheng S, Deng H, Kopyt N, Martin KJ, Rastogi A, Ureña-Torres P, Vervloet M, Block GA.

Nephrol Dial Transplant. 2019 Mar 11. pii: gfz039. doi: 10.1093/ndt/gfz039. [Epub ahead of print]

PMID:
30859218
6.

Efficacy and Safety of Tenapanor in Patients with Hyperphosphatemia Receiving Maintenance Hemodialysis: A Randomized Phase 3 Trial.

Block GA, Rosenbaum DP, Yan A, Chertow GM.

J Am Soc Nephrol. 2019 Apr;30(4):641-652. doi: 10.1681/ASN.2018080832. Epub 2019 Mar 7.

PMID:
30846557
7.

Effect of ferric citrate on serum phosphate and fibroblast growth factor 23 among patients with nondialysis-dependent chronic kidney disease: path analyses.

Block GA, Pergola PE, Fishbane S, Martins JG, LeWinter RD, Uhlig K, Neylan JF, Chertow GM.

Nephrol Dial Transplant. 2018 Oct 30. doi: 10.1093/ndt/gfy318. [Epub ahead of print]

PMID:
30380116
8.

Effects of bardoxolone methyl on body weight, waist circumference and glycemic control in obese patients with type 2 diabetes mellitus and stage 4 chronic kidney disease.

Chertow GM, Appel GB, Block GA, Chin MP, Coyne DW, Goldsberry A, Kalantar-Zadeh K, Meyer CJ, Molitch ME, Pergola PE, Raskin P, Silva AL, Spinowitz B, Sprague SM, Rossing P.

J Diabetes Complications. 2018 Dec;32(12):1113-1117. doi: 10.1016/j.jdiacomp.2018.09.005. Epub 2018 Sep 13.

9.

Effects of calcimimetics on long-term outcomes in dialysis patients: literature review and Bayesian meta-analysis.

Lozano-Ortega G, Waser N, Bensink ME, Goring S, Bennett H, Block GA, Chertow GM, Trotman ML, Cooper K, Levy AR, Belozeroff V.

J Comp Eff Res. 2018 Jul;7(7):693-707. doi: 10.2217/cer-2018-0015. Epub 2018 May 15.

PMID:
29762046
10.

Effects of vadadustat on hemoglobin concentrations in patients receiving hemodialysis previously treated with erythropoiesis-stimulating agents.

Haase VH, Chertow GM, Block GA, Pergola PE, deGoma EM, Khawaja Z, Sharma A, Maroni BJ, McCullough PA.

Nephrol Dial Transplant. 2019 Jan 1;34(1):90-99. doi: 10.1093/ndt/gfy055.

11.

The effects of tenapanor on serum fibroblast growth factor 23 in patients receiving hemodialysis with hyperphosphatemia.

Block GA, Rosenbaum DP, Yan A, Greasley PJ, Chertow GM, Wolf M.

Nephrol Dial Transplant. 2019 Feb 1;34(2):339-346. doi: 10.1093/ndt/gfy061.

12.

Hemoglobin response to ferric citrate in patients with nondialysis-dependent chronic kidney disease and iron deficiency anemia.

Pergola PE, Fishbane S, LeWinter RD, Neylan JF, Uhlig K, Block GA, Chertow GM.

Am J Hematol. 2018 Jun;93(6):E154-E156. doi: 10.1002/ajh.25088. Epub 2018 Mar 30. No abstract available.

13.

Diagnosis, Evaluation, Prevention, and Treatment of Chronic Kidney Disease-Mineral and Bone Disorder: Synopsis of the Kidney Disease: Improving Global Outcomes 2017 Clinical Practice Guideline Update.

Ketteler M, Block GA, Evenepoel P, Fukagawa M, Herzog CA, McCann L, Moe SM, Shroff R, Tonelli MA, Toussaint ND, Vervloet MG, Leonard MB.

Ann Intern Med. 2018 Mar 20;168(6):422-430. doi: 10.7326/M17-2640. Epub 2018 Feb 20.

PMID:
29459980
14.

Bardoxolone Methyl Improves Kidney Function in Patients with Chronic Kidney Disease Stage 4 and Type 2 Diabetes: Post-Hoc Analyses from Bardoxolone Methyl Evaluation in Patients with Chronic Kidney Disease and Type 2 Diabetes Study.

Chin MP, Bakris GL, Block GA, Chertow GM, Goldsberry A, Inker LA, Heerspink HJL, O'Grady M, Pergola PE, Wanner C, Warnock DG, Meyer CJ.

Am J Nephrol. 2018;47(1):40-47. doi: 10.1159/000486398. Epub 2018 Jan 18.

15.

Safety and efficacy of ferric citrate in patients with nondialysis-dependent chronic kidney disease.

Chertow GM, Block GA, Neylan JF, Pergola PE, Uhlig K, Fishbane S.

PLoS One. 2017 Nov 29;12(11):e0188712. doi: 10.1371/journal.pone.0188712. eCollection 2017.

16.

Variation in Sodium Intake and Intra-individual Change in Blood Pressure in Chronic Kidney Disease.

Pathak CM, Ix JH, Anderson CAM, Woodell TB, Smits G, Persky MS, Block GA, Rifkin DE.

J Ren Nutr. 2018 Mar;28(2):125-128. doi: 10.1053/j.jrn.2017.07.002. Epub 2017 Aug 31.

17.

Executive summary of the 2017 KDIGO Chronic Kidney Disease-Mineral and Bone Disorder (CKD-MBD) Guideline Update: what's changed and why it matters.

Ketteler M, Block GA, Evenepoel P, Fukagawa M, Herzog CA, McCann L, Moe SM, Shroff R, Tonelli MA, Toussaint ND, Vervloet MG, Leonard MB.

Kidney Int. 2017 Jul;92(1):26-36. doi: 10.1016/j.kint.2017.04.006. Review. Erratum in: Kidney Int. 2017 Dec;92(6):1558.

18.

Dosing of Etelcalcetide vs Cinacalcet for Secondary Hyperparathyroidism-Reply.

Block GA, Chertow GM.

JAMA. 2017 May 23;317(20):2132-2133. doi: 10.1001/jama.2017.4746. No abstract available.

PMID:
28535231
19.

Effect of Tenapanor on Serum Phosphate in Patients Receiving Hemodialysis.

Block GA, Rosenbaum DP, Leonsson-Zachrisson M, Åstrand M, Johansson S, Knutsson M, Langkilde AM, Chertow GM.

J Am Soc Nephrol. 2017 Jun;28(6):1933-1942. doi: 10.1681/ASN.2016080855. Epub 2017 Feb 3.

20.

Targeting Hypoxia-Inducible Factors for the Treatment of Anemia in Chronic Kidney Disease Patients.

Locatelli F, Fishbane S, Block GA, Macdougall IC.

Am J Nephrol. 2017;45(3):187-199. doi: 10.1159/000455166. Epub 2017 Jan 25. Review.

21.

Effect of Etelcalcetide vs Cinacalcet on Serum Parathyroid Hormone in Patients Receiving Hemodialysis With Secondary Hyperparathyroidism: A Randomized Clinical Trial.

Block GA, Bushinsky DA, Cheng S, Cunningham J, Dehmel B, Drueke TB, Ketteler M, Kewalramani R, Martin KJ, Moe SM, Patel UD, Silver J, Sun Y, Wang H, Chertow GM.

JAMA. 2017 Jan 10;317(2):156-164. doi: 10.1001/jama.2016.19468.

22.

Effect of Etelcalcetide vs Placebo on Serum Parathyroid Hormone in Patients Receiving Hemodialysis With Secondary Hyperparathyroidism: Two Randomized Clinical Trials.

Block GA, Bushinsky DA, Cunningham J, Drueke TB, Ketteler M, Kewalramani R, Martin KJ, Mix TC, Moe SM, Patel UD, Silver J, Spiegel DM, Sterling L, Walsh L, Chertow GM.

JAMA. 2017 Jan 10;317(2):146-155. doi: 10.1001/jama.2016.19456.

23.

Effects of Ferric Citrate in Patients with Nondialysis-Dependent CKD and Iron Deficiency Anemia.

Fishbane S, Block GA, Loram L, Neylan J, Pergola PE, Uhlig K, Chertow GM.

J Am Soc Nephrol. 2017 Jun;28(6):1851-1858. doi: 10.1681/ASN.2016101053. Epub 2017 Jan 12.

24.

Blood Calcification Propensity, Cardiovascular Events, and Survival in Patients Receiving Hemodialysis in the EVOLVE Trial.

Pasch A, Block GA, Bachtler M, Smith ER, Jahnen-Dechent W, Arampatzis S, Chertow GM, Parfrey P, Ma X, Floege J.

Clin J Am Soc Nephrol. 2017 Feb 7;12(2):315-322. doi: 10.2215/CJN.04720416. Epub 2016 Dec 9.

25.

Geographic variation of parathyroidectomy in patients receiving hemodialysis: a retrospective cohort analysis.

Wetmore JB, Liu J, Dluzniewski PJ, Ishani A, Block GA, Collins AJ.

BMC Surg. 2016 Nov 29;16(1):77.

26.

Facility-level CKD-MBD composite score and risk of adverse clinical outcomes among patients on hemodialysis.

Block GA, Yusuf AA, Danese MD, Wirtz HS, Hu Y, Do TP, Cooper K, Gilbertson DT, Bradbury BD, Collins AJ.

BMC Nephrol. 2016 Nov 4;17(1):166.

27.

Patiromer Decreases Serum Potassium and Phosphate Levels in Patients on Hemodialysis.

Bushinsky DA, Rossignol P, Spiegel DM, Benton WW, Yuan J, Block GA, Wilcox CS, Agarwal R.

Am J Nephrol. 2016;44(5):404-410. Epub 2016 Oct 27.

28.

Iron citrate reduces high phosphate-induced vascular calcification by inhibiting apoptosis.

Ciceri P, Elli F, Braidotti P, Falleni M, Tosi D, Bulfamante G, Block GA, Cozzolino M.

Atherosclerosis. 2016 Nov;254:93-101. doi: 10.1016/j.atherosclerosis.2016.09.071. Epub 2016 Sep 30.

PMID:
27716569
29.

Effect of Patiromer on Urinary Ion Excretion in Healthy Adults.

Bushinsky DA, Spiegel DM, Gross C, Benton WW, Fogli J, Hill Gallant KM, Du Mond C, Block GA, Weir MR, Pitt B.

Clin J Am Soc Nephrol. 2016 Oct 7;11(10):1769-1776. doi: 10.2215/CJN.01170216. Epub 2016 Sep 27.

30.

Spot urine sodium measurements do not accurately estimate dietary sodium intake in chronic kidney disease.

Dougher CE, Rifkin DE, Anderson CA, Smits G, Persky MS, Block GA, Ix JH.

Am J Clin Nutr. 2016 Aug;104(2):298-305. doi: 10.3945/ajcn.115.127423. Epub 2016 Jun 29.

31.

Effect of Tenapanor on Interdialytic Weight Gain in Patients on Hemodialysis.

Block GA, Rosenbaum DP, Leonsson-Zachrisson M, Stefansson BV, Rydén-Bergsten T, Greasley PJ, Johansson SA, Knutsson M, Carlsson BC.

Clin J Am Soc Nephrol. 2016 Sep 7;11(9):1597-605. doi: 10.2215/CJN.09050815. Epub 2016 Jun 23.

32.

Ferric Citrate in Patients With Chronic Kidney Disease.

Block GA.

Semin Nephrol. 2016 Mar;36(2):130-5. doi: 10.1016/j.semnephrol.2016.02.008. Review.

PMID:
27236135
33.

Treatment of Secondary Hyperparathyroidism: Results of a Phase 2 Trial Evaluating an Intravenous Peptide Agonist of the Calcium-Sensing Receptor.

Bushinsky DA, Block GA, Martin KJ, Bell G, Huang S, Sun Y, Spiegel DM, Walsh L, Mix TC, Kewalramani R.

Am J Nephrol. 2015;42(5):379-88. doi: 10.1159/000442754. Epub 2015 Dec 19.

PMID:
26684933
34.

Lessons Learned from EVOLVE for Planning of Future Randomized Trials in Patients on Dialysis.

Parfrey PS, Block GA, Correa-Rotter R, Drüeke TB, Floege J, Herzog CA, London GM, Mahaffey KW, Moe SM, Wheeler DC, Chertow GM.

Clin J Am Soc Nephrol. 2016 Mar 7;11(3):539-46. doi: 10.2215/CJN.06370615. Epub 2015 Nov 27. Review.

35.

Cinacalcet, dialysate calcium concentration, and cardiovascular events in the EVOLVE trial.

Pun PH, Abdalla S, Block GA, Chertow GM, Correa-Rotter R, Dehmel B, Drüeke TB, Floege J, Goodman WG, Herzog CA, London GM, Mahaffey KW, Moe SM, Parfrey PS, Wheeler DC, Middleton JP.

Hemodial Int. 2016 Jul;20(3):421-31. doi: 10.1111/hdi.12382. Epub 2015 Nov 13.

36.

Understanding barriers to home-based and self-care in-center hemodialysis.

Yau M, Carver M, Alvarez L, Block GA, Chertow GM.

Hemodial Int. 2016 Apr;20(2):235-41. doi: 10.1111/hdi.12357. Epub 2015 Sep 28.

PMID:
26415746
37.

Changes in secondary hyperparathyroidism-related biochemical parameters and medication use following parathyroidectomy.

Wetmore JB, Liu J, Do TP, Lowe KA, Ishani A, Bradbury BD, Block GA, Collins AJ.

Nephrol Dial Transplant. 2016 Jan;31(1):103-11. doi: 10.1093/ndt/gfv291. Epub 2015 Aug 19.

PMID:
26292694
38.

Cinacalcet, Fibroblast Growth Factor-23, and Cardiovascular Disease in Hemodialysis: The Evaluation of Cinacalcet HCl Therapy to Lower Cardiovascular Events (EVOLVE) Trial.

Moe SM, Chertow GM, Parfrey PS, Kubo Y, Block GA, Correa-Rotter R, Drüeke TB, Herzog CA, London GM, Mahaffey KW, Wheeler DC, Stolina M, Dehmel B, Goodman WG, Floege J; Evaluation of Cinacalcet HCl Therapy to Lower Cardiovascular Events (EVOLVE) Trial Investigators*.

Circulation. 2015 Jul 7;132(1):27-39. doi: 10.1161/CIRCULATIONAHA.114.013876. Epub 2015 Jun 9.

PMID:
26059012
39.

The effects of cinacalcet on blood pressure, mortality and cardiovascular endpoints in the EVOLVE trial.

Chang TI, Abdalla S, London GM, Block GA, Correa-Rotter R, Drüeke TB, Floege J, Herzog CA, Mahaffey KW, Moe SM, Parfrey PS, Wheeler DC, Dehmel B, Goodman WG, Chertow GM.

J Hum Hypertens. 2016 Mar;30(3):204-9. doi: 10.1038/jhh.2015.56. Epub 2015 Jun 4.

PMID:
26040438
40.

Rationale and Approaches to Phosphate and Fibroblast Growth Factor 23 Reduction in CKD.

Isakova T, Ix JH, Sprague SM, Raphael KL, Fried L, Gassman JJ, Raj D, Cheung AK, Kusek JW, Flessner MF, Wolf M, Block GA.

J Am Soc Nephrol. 2015 Oct;26(10):2328-39. doi: 10.1681/ASN.2015020117. Epub 2015 May 12. Review.

41.

Refining the definition of clinically important mineral and bone disorder in hemodialysis patients.

Danese MD, Halperin M, Lowe KA, Bradbury BD, Do TP, Block GA.

Nephrol Dial Transplant. 2015 Aug;30(8):1336-44. doi: 10.1093/ndt/gfv034. Epub 2015 Mar 27.

42.

A randomized, double-blind, phase 2 study evaluating the safety and efficacy of AMG 416 for the treatment of secondary hyperparathyroidism in hemodialysis patients.

Bell G, Huang S, Martin KJ, Block GA.

Curr Med Res Opin. 2015 May;31(5):943-52. doi: 10.1185/03007995.2015.1031731.

PMID:
25786369
43.

The Effects of Cinacalcet in Older and Younger Patients on Hemodialysis: The Evaluation of Cinacalcet HCl Therapy to Lower Cardiovascular Events (EVOLVE) Trial.

Parfrey PS, Drüeke TB, Block GA, Correa-Rotter R, Floege J, Herzog CA, London GM, Mahaffey KW, Moe SM, Wheeler DC, Kubo Y, Dehmel B, Goodman WG, Chertow GM; Evaluation of Cinacalcet HCl Therapy to Lower Cardiovascular Events (EVOLVE) Trial Investigators.

Clin J Am Soc Nephrol. 2015 May 7;10(5):791-9. doi: 10.2215/CJN.07730814. Epub 2015 Feb 20.

44.

Clinical outcomes after parathyroidectomy in a nationwide cohort of patients on hemodialysis.

Ishani A, Liu J, Wetmore JB, Lowe KA, Do T, Bradbury BD, Block GA, Collins AJ.

Clin J Am Soc Nephrol. 2015 Jan 7;10(1):90-7. doi: 10.2215/CJN.03520414. Epub 2014 Dec 16.

45.

Effects of Cinacalcet on Fracture Events in Patients Receiving Hemodialysis: The EVOLVE Trial.

Moe SM, Abdalla S, Chertow GM, Parfrey PS, Block GA, Correa-Rotter R, Floege J, Herzog CA, London GM, Mahaffey KW, Wheeler DC, Dehmel B, Goodman WG, Drüeke TB; Evaluation of Cinacalcet HCl Therapy to Lower Cardiovascular Events (EVOLVE) Trial Investigators.

J Am Soc Nephrol. 2015 Jun;26(6):1466-75. doi: 10.1681/ASN.2014040414. Epub 2014 Dec 11.

46.

A 12-week, double-blind, placebo-controlled trial of ferric citrate for the treatment of iron deficiency anemia and reduction of serum phosphate in patients with CKD Stages 3-5.

Block GA, Fishbane S, Rodriguez M, Smits G, Shemesh S, Pergola PE, Wolf M, Chertow GM.

Am J Kidney Dis. 2015 May;65(5):728-36. doi: 10.1053/j.ajkd.2014.10.014. Epub 2014 Nov 4.

47.

Increasing hip fractures in patients receiving hemodialysis and peritoneal dialysis.

Mathew AT, Hazzan A, Jhaveri KD, Block GA, Chidella S, Rosen L, Wagner J, Fishbane S.

Am J Nephrol. 2014;40(5):451-7. doi: 10.1159/000369039. Epub 2014 Nov 26.

PMID:
25427771
48.

Effects of cinacalcet on atherosclerotic and nonatherosclerotic cardiovascular events in patients receiving hemodialysis: the EValuation Of Cinacalcet HCl Therapy to Lower CardioVascular Events (EVOLVE) trial.

Wheeler DC, London GM, Parfrey PS, Block GA, Correa-Rotter R, Dehmel B, Drüeke TB, Floege J, Kubo Y, Mahaffey KW, Goodman WG, Moe SM, Trotman ML, Abdalla S, Chertow GM, Herzog CA; EValuation Of Cinacalcet HCl Therapy to Lower CardioVascular Events (EVOLVE) Trial Investigators.

J Am Heart Assoc. 2014 Nov 17;3(6):e001363. doi: 10.1161/JAHA.114.001363. Erratum in: J Am Heart Assoc. 2015 Jan;4(1):e000570.

49.

Effect of dietary phosphate intake on the circadian rhythm of serum phosphate concentrations in chronic kidney disease: a crossover study.

Ix JH, Anderson CA, Smits G, Persky MS, Block GA.

Am J Clin Nutr. 2014 Nov;100(5):1392-7. doi: 10.3945/ajcn.114.085498. Epub 2014 Aug 27.

50.

Estimation of 24-hour urine phosphate excretion from spot urine collection: development of a predictive equation.

Robinson-Cohen C, Ix JH, Smits G, Persky M, Chertow GM, Block GA, Kestenbaum BR.

J Ren Nutr. 2014 May;24(3):194-9. doi: 10.1053/j.jrn.2014.02.001.

PMID:
24759300

Supplemental Content

Loading ...
Support Center